Fig. 4.

Ablation of DHX32 inhibits the tumorigenicity of CRC cells. (a & b) SW480 cells with or without depletion of DHX32 were grafted to the flank of nude mice by injecting the cells subcutaneously to observe tumor development, and volumes of tumor were determined and plotted as mean ± SD of six independent experiments. (c) Expression levels of DHX32, β-catenin and CD31 in transplanted tumor tissues were determined by immunohistochemistry analysis. The scale bars indicate 100 μm. (d) Statistical analyses of expression of DHX32, β-catenin and CD31 in DHX32 depletion and control tumors. *P < 0.05.